Puma Biotechnology Files 8-K
Ticker: PBYI · Form: 8-K · Filed: Aug 7, 2024 · CIK: 1401667
| Field | Detail |
|---|---|
| Company | Puma Biotechnology, Inc. (PBYI) |
| Form Type | 8-K |
| Filed Date | Aug 7, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $107,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, other-events
Related Tickers: PBYI
TL;DR
PUMA filed an 8-K for 'Other Events' - details TBD.
AI Summary
On August 6, 2024, Puma Biotechnology, Inc. filed an 8-K report to disclose other events. The filing does not contain specific details about the nature of these events, dollar amounts, or other parties involved.
Why It Matters
This filing indicates that Puma Biotechnology has reported an event requiring immediate disclosure to the SEC, though the specifics are not yet detailed.
Risk Assessment
Risk Level: low — The filing is a standard disclosure of 'Other Events' without immediate financial or operational impact details, making the immediate risk low.
Key Players & Entities
- PUMA BIOTECHNOLOGY, INC. (company) — Registrant
- August 6, 2024 (date) — Date of earliest event reported
- 10880 Wilshire Blvd, Suite 2150 Los Angeles, CA 90024 (address) — Principal executive offices
FAQ
What specific event(s) are being reported under 'Other Events'?
The filing does not specify the nature of the 'Other Events' being reported.
When was the earliest event reported in this filing?
The earliest event reported was on August 6, 2024.
What is Puma Biotechnology, Inc.'s principal executive office address?
The principal executive offices are located at 10880 Wilshire Blvd, Suite 2150, Los Angeles, CA 90024.
What is the company's state of incorporation?
Puma Biotechnology, Inc. is incorporated in Delaware.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number is 77-0683487.
Filing Stats: 1,022 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2024-08-07 09:00:09
Key Financial Figures
- $0.0001 — on which registered Common Stock , $0.0001 par value per share PBYI The Nasdaq
- $107,500,000 — ugh December 31, 2023, in the amount of $107,500,000. A separate bench trial related to cert
Filing Documents
- pbyi20240806_8k.htm (8-K) — 31KB
- 0001437749-24-025027.txt ( ) — 161KB
- pbyi-20240806.xsd (EX-101.SCH) — 3KB
- pbyi-20240806_def.xml (EX-101.DEF) — 11KB
- pbyi-20240806_lab.xml (EX-101.LAB) — 15KB
- pbyi-20240806_pre.xml (EX-101.PRE) — 11KB
- pbyi20240806_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events On September 22, 2021, the Company filed suit against AstraZeneca Pharmaceuticals, LP, AstraZeneca AB, and AstraZeneca PLC for infringement of United States Patent Nos. 10,603,314 ("the '314 patent") and 10,596,162 ("the '162 patent") (Puma Biotechnology, Inc. et al. v. AstraZeneca Pharmaceuticals LP et al., 1:21CV01338 (D. Del. Sep. 22, 2021)). The Company's complaint alleges that AstraZeneca's commercial manufacture, use, offer for sale, sale, distribution, and/or importation of Tagrisso (osimertinib) products for the treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancer infringes the '314 and '162 patents. The Company is an exclusive licensee of the '314 and '162 patents under the Pfizer Agreement. Wyeth is a co-plaintiff. Plaintiffs seek a judgment that AstraZeneca's product infringes the asserted patents and an award of monetary damages in an amount to be proven at trial. AstraZeneca AB and AstraZeneca Pharmaceuticals LP filed an answer and counterclaims on November 5, 2021, including claims challenging the asserted patents as not infringed and/or invalid, and accusing plaintiffs of unclean hands and patent misuse. The parties stipulated to dismiss AstraZeneca PLC as a defendant and Pfizer as a Counterclaim Defendant on December 10, 2021, which the Court so ordered on December 13, 2021. The Company filed its answer to AstraZeneca's counterclaims on December 17, 2021, denying those claims. The case was reassigned to visiting Judge Matthew Kennelly of the Northern District of Illinois. A Markman Hearing was conducted on March 17, 2023, and the Court issued its claim construction decision on March 29, 2023. Fact discovery closed on May 19, 2023, and expert discovery closed on November 17, 2023. The Court denied the parties' respective motions for summary judgment and Daubert motions, other than to clarify that Plaintiffs' damages cannot extend to any time period before the asserted patents were issued. The Court gra
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Puma Biotechnology, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 7, 2024 PUMA BIOTECHNOLOGY, INC. a Delaware Corporation By: /s/ Alan Auerbach Name: Alan H. Auerbach Title: Chief Executive Officer, President and Chairman of the Board